Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
Surfen Sie die heißeste Edelmetall-Welle des Jahrzehnts! Dieses TOP-Unternehmen zündet nächste Wachstumsstufe!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QD66 | ISIN: KYG3224E1061 | Ticker-Symbol: 6HN
Frankfurt
04.07.25 | 08:05
7,150 Euro
+5,15 % +0,350
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
EVEREST MEDICINES LTD Chart 1 Jahr
5-Tage-Chart
EVEREST MEDICINES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
7,1007,35019:03
7,1007,35004.07.

Aktuelle News zur EVEREST MEDICINES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrEverest Medicines Limited: Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation236HONG KONG, July 4, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai....
► Artikel lesen
FrEverest Medicines targets global expansion with proprietary, AI-driven mRNA platform4
27.06.EVEREST MED (01952): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, 27 JUNE 2025-
EVEREST MEDICINES Aktie jetzt für 0€ handeln
26.06.Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 20252
13.06.EVEREST MED (01952): VOLUNTARY ANNOUNCEMENT1
12.06.Everest Medicines Limited: NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances249- Kidney Disease Treatment into a New Era of Precision ManagementHONG KONG, June 12, 2025 - (ACN Newswire) - At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented...
► Artikel lesen
09.06.Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association66EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other...
► Artikel lesen
09.06.Everest Medicines Limited: Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025316HONG KONG, June 9, 2025 - (ACN Newswire) - At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation...
► Artikel lesen
03.06.EVEREST MED (01952): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - VIRTUAL MEETING ARRANGEMENTS FOR THE ANNUAL GENERAL MEETING1
03.06.EVEREST MED (01952): THE PRE-IPO EMPLOYEE EQUITY PLAN1
03.06.EVEREST MED (01952): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 27 JUNE 2025-
03.06.EVEREST MED (01952): NOTICE OF ANNUAL GENERAL MEETING-
03.06.EVEREST MED (01952): (1) PROPOSED RE-ELECTION OF DIRECTORS; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES; (3) PROPOSED ...-
07.05.Everest Medicines Limited: Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China256HONG KONG, May 7, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National...
► Artikel lesen
07.05.EVEREST MED (01952): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE FULL APPROVAL OF NEFECON BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THE TREATMENT ...3
25.04.EVEREST MED-B (01952): REMOVAL OF STOCK MARKER "B"1
24.04.EVEREST MED-B (01952): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT-
24.04.EVEREST MED-B (01952): 2024 ANNUAL REPORT-
22.04.Everest Medicines Limited: Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange353SHANGHAI, CHINA, Apr 22, 2025 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...
► Artikel lesen
22.04.EVEREST MED-B (01952): DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES-
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1